Starting in November, doctors will use, a new Ebola virus vaccine that is better suited for broad-based prophylaxis than the existing vaccine currently being used to combat the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC).
The trial will evaluate the safety, tolerability, and immunogenicity of MVA-BN WEV in 45 healthy adults in three treatment groups receiving different doses of the vaccine.
Identifying and vaccinating Ebola patient contacts is crucial to protect people at risk and poses one of the major challenges in containing the outbreak.
The US Food and Drug Administration (FDA) has given approval of Jynneos Smallpox and Monkeypox Vaccine, Live, This is the only currently FDA-approved vaccine for the prevention of monkeypox disease.
The US Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) will work with BioFactura, Inc., providing expertise and $9.5 million over two years to develop a monoclonal antibody treatment for smallpox. BARDA has options to support additional work, providing up to a total of $67.4 million over five years.
Three years ago, health officials phasied out a problematic component of the polio vaccine used in developing countries, and introduced a version that they hoped would put the world on a better footing to eradicate the disease. Now, some health officials are weighing whether “the switch,” as the process was known, needs to be reversed because they fear the new vaccine heightens the risk of the disease spreading indevelopin nations.
The 10-day campaign in parts of Ebonyi, Benue , and Cross River States, seeks to vaccinate 1.6 million people to contain a yellow fever outbreak.
The US Department of Health and Human Services (HHS) issued contract supports the continued supply of ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) into the US Strategic National Stockpile.
The GEO-LM01 vaccine discussed in this paper provides two sources of viral antigens that mimic a natural viral infection promoting predominantly a balanced T cell response, which is critical for protection against Lassa virus infection.
Scientists have genetically manipulated a harmless form of E. coli to create a vaccine that protects against a hypervirulent form of Klebsiella pneumoniae in mice.